LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $7.00

LifeStance Health Group (NASDAQ:LFST) had its target price upped by Barclays from $6.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an underweight rating on the stock.

Separately, UBS Group lowered their target price on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, LifeStance Health Group has a consensus rating of “Hold” and an average target price of $8.42.

LifeStance Health Group Stock Down 2.4 %

LifeStance Health Group stock opened at $7.22 on Monday. The company has a market capitalization of $2.76 billion, a P/E ratio of -27.77 and a beta of 1.24. LifeStance Health Group has a 1-year low of $4.64 and a 1-year high of $9.20. The firm’s fifty day simple moving average is $6.97 and its 200-day simple moving average is $6.23. The company has a current ratio of 1.32, a quick ratio of 1.22 and a debt-to-equity ratio of 0.19.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to the consensus estimate of $302.25 million. During the same quarter in the prior year, the company posted ($0.17) EPS. The firm’s revenue was up 18.9% on a year-over-year basis. Sell-side analysts forecast that LifeStance Health Group will post -0.22 earnings per share for the current fiscal year.

Insider Activity at LifeStance Health Group

In other news, insider Ann Varanakis sold 5,269 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $6.28, for a total transaction of $33,089.32. Following the transaction, the insider now owns 263,007 shares in the company, valued at approximately $1,651,683.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Asset Management Inc acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at $53,000. Bessemer Group Inc. raised its position in LifeStance Health Group by 43.4% in the first quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock worth $56,000 after purchasing an additional 2,768 shares in the last quarter. Algert Global LLC bought a new position in LifeStance Health Group during the second quarter worth about $57,000. Victory Capital Management Inc. boosted its holdings in LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after purchasing an additional 3,063 shares in the last quarter. Finally, Park Edge Advisors LLC bought a new stake in shares of LifeStance Health Group in the 3rd quarter valued at approximately $73,000. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.